Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease
21 Nov 2025
byDr. Gardian Chung-Yan Fong, Specialist in Neurology, Private practice, Hong Kong; Sonny Fong-Kwong Hon, Specialist in Neurology, Private practice, Hong Kong; Dr. William Shing-Kee Cheung, Specialist in Nuclear Medicine, Hong Kong Sanatorium & Hospital, Hong Kong; Dr. Sam Kwan-Kit Wu, Specialist in Nuclear Medicine, Hong Kong Sanatorium & Hospital, Hong Kong
Two Hong Kong patients achieved clinical stabilization along with amyloid burden reduction after ≥12 months of lecanemab treatment.
Clinically meaningful benefits and biological clearance of amyloid load after initiating and continuing lecanemab treatment in two patients with Alzheimer’s disease
21 Nov 2025
